stockrowBillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) Return on invested capital
BillionToOne, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 24.0 percentage points from fiscal 2025 (24.0%). That is in line with the Diagnostics & Research industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 24.0% | 24.01 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CDNA CareDx, Inc. compare | 33.6% |
| SHC Sotera Health Company compare | 9.80% |
| QGEN QIAGEN N.V. compare | 6.62% |
| VCYT Veracyte, Inc. compare | 4.33% |
| RDNT RadNet, Inc. compare | 2.24% |
| ADPT Adaptive Biotechnologies Corporation compare | 0.00% |
| BLLN BillionToOne, Inc. | 0.00% |
| NEO NeoGenomics, Inc. compare | −2.97% |
| GRAL GRAIL, Inc. compare | −14.7% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on BLLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement